MarcStevenGreenblattMD
Oncology • Burlington, VTAssociate Professor, Medicine, University of Vermont College of Medicine
Are you Dr. Greenblatt?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 48 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
111 Colchester Ave
Burlington, VT 05401Phone+1 802-847-8400
Summary
- Dr. Marc Greenblatt, MD is an oncologist in Burlington, Vermont. He is currently licensed to practice medicine in Vermont, New York, and New Mexico. He is affiliated with University of Vermont Medical Center and is an Associate Professor at University of Vermont College of Medicine.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1992 - 1993
University of New Mexico School of MedicineFellowship, Hematology and Medical Oncology, 1988 - 1991- University of New Mexico School of MedicineResidency, Internal Medicine, 1983 - 1987
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1983
Certifications & Licensure
NY State Medical License 2019 - 2026
VT State Medical License 1995 - 2024
NM State Medical License 1984 - 2000- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
- Effectiveness of Aprepitant in Addition to Ondansetron in the Prevention of Nausea and Vomiting Caused by Upper Abdominal Radiotherapy Start of enrollment: 2009 Oct 01
Publications & Presentations
PubMed
- 363 citationsApplication of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific databaseBryony A. Thompson, Amanda B. Spurdle, John-Paul Plazzer, Marc S. Greenblatt, Kiwamu Akagi
Nature Genetics. 2014-02-01 - 212 citationsCancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database.Mev Dominguez-Valentin, Julian R Sampson, Toni T Seppälä, Sanne W Ten Broeke, John-Paul Plazzer
Genetics in Medicine. 2020-01-01 - 291 citationsRecommendations for application of the functional evidence PS3/BS3 criterion using the ACMG/AMP sequence variant interpretation framework.Sarah E. Brnich, Ahmad N. Abou Tayoun, Fergus J. Couch, Garry R. Cutting, Marc S. Greenblatt
Genome Medicine. 2020-12-01
Press Mentions
Risk-Reducing Hysterectomy and Bilateral Salpingo-Oophorectomy in Female Heterozygotes of Pathogenic Mismatch Repair Variants: A Prospective Lynch Syndrome Database ReportDecember 1st, 2020
Study Provides Clearer Picture of Cancer RiskJanuary 27th, 2014
Grant Support
- Computational &Laboratory Study Of P16/Ink4 MutationsNational Cancer Institute2002–2004
- Computational &Laboratory Study Of P16/Ink4 MutationsNational Cancer Institute2002
- Mutations In The HPRT Gene, Smoking And Lung CancerNational Center For Research Resources1997–2000
